Epp clinical trials

Explore recruiting epp clinical trials.

Recruiting epp studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Epp trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

MT-7117-A-302 Study: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Adults and Adolescents with Erythropoietic Protoporphyria or X-Linked Protoporphyria

Spain, Bulgaria, Netherlands, France, Czechia, Poland +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Study to Evaluate the Pharmacokinetics of Afamelanotide in Patients with Erythropoietic Protoporphyria (EPP).

Belgium, Netherlands

Phase I and Phase II (Integrated)- Other EU CTIS Study details

APOLLO: A Randomized, Double-Blind, Placebo-Controlled Study of Bitopertin to Evaluate the Efficacy, Safety, and Tolerability in Participants with Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

Germany, Ireland, Spain, France, Norway, Netherlands +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects with Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

Norway, Sweden, Italy, Spain, Germany, Bulgaria +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

HELIOS: An Open-Label, Long-Term Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants with Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP).

Italy, France, Ireland, Belgium, Sweden, Germany +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

FLUCLORIC - Randomized multicentric Phase III study comparing the efficacy of two reduced intensity conditioning regimens (clofarabine/busulfan versus fludarabine/busulfan) in adults with acute myeloid leukemia and eligible to allogeneic stem cell transplantation: a SFGM-TC study

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Epp trials by city

Epp in Toronto Epp in Vancouver Epp in Montreal Epp in Calgary Epp in Edmonton Epp in Ottawa Epp in Winnipeg Epp in Quebec City Epp in Hamilton Epp in Kitchener Epp in London Epp in Halifax Epp in New York Epp in Los Angeles Epp in Chicago Epp in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease